# US 2021/0171439 A1 · Hepatitis b capsid assembly modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171439 A1
- Document ID: US20210171439A1
- Status: Published application
- Kind: A1
- Application number: 16/771,387
- Filed: 2018-12-10
- Published: 2021-06-10
- Earliest claimed: 2017-12-11
- Assignees: Venatorx Pharmaceuticals, Inc.
- Applicants: VenatoRx Pharmaceuticals, Inc.
- Inventors: Christopher J. BURNS; Glen COBURN; Bin LIU; Jiangchao YAO; Christopher BENETATOS; Steven A. Boyd; Stephen M. CONDON
- Web page: https://patentgrep.com/patent/US20210171439A1

## CPC

- A61P 31/20: for DNA viruses
- C07C 233/64: having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07C 233/66: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C 235/56: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 207/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 207/12: Oxygen or sulfur atoms
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 207/416: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D 211/44: attached in position 4
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 211/48: having an acyclic carbon atom attached in position 4
- C07D 211/58: attached in position 4
- C07D 211/62: attached in position 4
- C07D 211/70: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 213/40: Acylated substituent nitrogen atom
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 223/08: Oxygen atoms
- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 265/30: not condensed with other rings
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 295/185: from aliphatic carboxylic acids
- C07D 307/22: Nitrogen atoms not forming part of a nitro radical
- C07D 307/66: Nitrogen atoms
- C07D 309/14: Nitrogen atoms not forming part of a nitro radical
- C07D 319/12: not condensed with other rings
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 451/04: with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D 451/06: Oxygen atoms
- C07D 471/04: Ortho-condensed systems
- C07D 471/08: Bridged systems
- C07D 471/10: Spiro-condensed systems
- C07D 471/18: Bridged systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/08: Bridged systems
- C07D 498/04: Ortho-condensed systems
- C07D 498/08: Bridged systems
- C07D 513/04: Ortho-condensed systems
- C07D 513/18: Bridged systems
- C07F 5/025: {Boronic and borinic acid compounds}
- C07C 2601/14: The ring being saturated
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

## Claims

### Claim 1

A compound of Formula (II), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
wherein:
Ring A is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
Ring B is
or C2-5heteroaryl;
R1 is —F, —Cl, —OH, or —OR;
R2 is hydrogen, —F, —Cl, —CN, —ORa, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, or C3-8cycloalkyl;
R3 is hydrogen or C1-6alkyl;
each R4 is independently halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C2-7heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R12;
or two R4 on adjacent atoms are taken together with the atoms to which they are attached to form a carbocycle ring or a heterocycle ring; each optionally substituted with one, two, or three R12;
each R5 is independently hydrogen, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C2-7heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R13;
or two Ron adjacent atoms are taken together with the atoms to which they are attached to form a carbocycle ring or a heterocycle ring; each optionally substituted with one, two, or three R13;
R6 and R7 are each independently hydrogen, C1-6alkyl, C1-6alkoxy, C2-6alkenyl, C2-6alkynyl, C3-15cycloalkyl, C2-15heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl); wherein each alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R10;
or R6 and R7 are taken together with the nitrogen atom to which they are attached to form a C2-15heterocycloalkyl or a C2-15heterocycloalkenyl; wherein each heterocycloalkyl and heterocycloalkenyl is independently optionally substituted with one, two, or three R11;
m is an integer from 0 to 5;
n is an integer from 0 to 4;
each R10 is independently oxo, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, —B(ORd)2, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C2-7heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl);
each R11 is independently oxo, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —NRS(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRbRc, —CH2C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbC(═O)CH2NRbRc, —C(═O)CH2NRbC(═O)NRbRc, —OP(═O)(ORb)(OR), —B(ORd)2, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, C1-6cyanoalkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C2-7heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl);
each R12 and R13 is independently halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, or C3-8cycloalkyl;
each Ra is independently C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, C3-8cycloalkyl, C2-7heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo, halogen, —OH, C1-6alkyl, or C1-6haloalkyl;
each Rb and Rc is independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, C3-8cycloalkyl, C2-7heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo, halogen, —OH, C1-6alkyl, or C1-6haloalkyl;
or Rb and Rc are taken together with the nitrogen atom to which they are attached to form a C2-7heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, —OH, C1-6alkyl, or C1-6haloalkyl; and
each R is independently hydrogen or C1-6alkyl;
or two Rd are taken together to form a C2-7heterocycloalkyl optionally substituted with one, two, or three halogen, —OH, or C1-6alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R1 is —F or —OH.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R1 is —F.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is hydrogen, —F, or C1-6alkyl.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is hydrogen or —F.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R2 is —F.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is hydrogen or methyl.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is hydrogen.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R3 is methyl.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is aryl or heteroaryl.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is aryl.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is C6-10aryl.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is phenyl.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is heteroaryl.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14)

The compound of any one of claims 1-10 or 14, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is C2-9heteroaryl.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 15)

The compound of any one of claims 1-10 or 14-15, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, or thiophenyl.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 15, 16)

The compound of any one of claims 1-10 or 14-16, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is pyridinyl, imidazolyl, pyrazolyl, thiazolyl, or thiophenyl.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 15, 16, 17)

The compound of any one of claims 1-10 or 14-17, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is pyridinyl.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is cycloalkyl or heterocycloalkyl.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 19)

The compound of any one of claims 1-9 or 19, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is cycloalkyl.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 19)

The compound of any one of claims 1-9 or 19, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring A is heterocycloalkyl.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R4 is independently halogen, —CN, —ORa, —NO2, —C(═O)NRbRc, C1-6alkyl, C1-6haloalkyl, or C3-8cycloalkyl.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound of any one of claims 1-22, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R4 is independently —F, —Cl, —Br, —CN, —OMe, —NO2, —C(═O)NH2, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, —CF3, —CHF2, CH2F, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R4 is independently —F, —Cl, —Br, —CN, —OMe, —NO2, —C(═O)NH2, —CF3, methyl, isopropyl, or cyclopropyl.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 1-24, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein m is 1 to 3.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 1-25, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein m is 1.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 1-25, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein m is 2.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein two R4 on adjacent atoms are taken together with the atoms to which they are attached to form a carbocycle ring or a heterocycle ring; each optionally substituted with one, two, or three R12.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 1-24, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 29)

The compound of any one of claims 1-25 or 29, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 29, 30)

The compound of any one of claims 1-25 or 29-30, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring B is C2-5heteroaryl.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 1-32, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring B is pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, or thiophenyl.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound of any one of claims 1-33, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring B is pyridinyl, pyrrolyl, thiazolyl, or thiophenyl.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound of any one of claims 1-33, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein
wherein,
Y is —N— or —CR5—;
Z is —NR—, —S—, or —O—;
R is hydrogen or C1-6alkyl;
each R5 is independently hydrogen, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C2-7heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R13;
or two R5 on adjacent atoms are taken together with the atoms to which they are attached to form a carbocycle ring or heterocycle ring; each optionally substituted with one, two, or three R13;
or R5 and R8 on adjacent atoms are taken together with the atoms to which they are attached to form a carbocycle ring or heterocycle ring optionally substituted with one, two, or three R13; and
each R13 is independently halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRbR10, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, or C3-8cycloalkyl.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 35)

The compound of any one of claims 1-33 or 35, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein
wherein
Ring C is a heterocycloalkyl or heteroaryl;
Y is —N— or —CR5—;
each R5 is independently hydrogen, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C2-7heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R13;
each R13 is independently halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, or C3-8cycloalkyl; and
r is 0 to 3.

### Claim 37 (depends on 36)

The compound of claim 36, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring C is a 4- to 7-membered heterocycloalkyl.

### Claim 38 (depends on 36, 37)

The compound of claim 36 or 37, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring C is a 5- to 6-membered heterocycloalkyl.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Ring B is

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound of any one of claims 1-39, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R is independently hydrogen, halogen, —CN, —ORa, C1-6haloalkyl, C1-6hydroxyalkyl, C2-6alkenyl, or C1-6alkyl.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The compound of any one of claims 1-40, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R is independently hydrogen, —F, —Cl, —Br, —OMe, —CH3, —CH═CH2, —CH(OH)CH2OH, —CH2F, —CHF2, or —CF3.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The compound of any one of claims 1-41, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R is independently hydrogen, —F, —Cl, —Br, —OMe, —CH═CH2, —CH(OH)CH2OH, or —CH3.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The compound of any one of claims 1-42, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein n is 0 to 2.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein n is 1.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound of any one of claims 1-44, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45)

The compound of any one of claims 1-40 or 45, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 46)

The compound of any one of claims 1-40 or 45-46, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The compound of any one of claims 1-47, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R6 is hydrogen or C1-6alkyl; wherein the alkyl is optionally substituted with one, two, or three R10.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 1-48, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R7 is C1-6alkyl, C1-6alkoxy, C3-15cycloalkyl, C2-15heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R10.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The compound of any one of claims 1-49, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R10 is independently halogen, —CN, —OH, —ORa, —NR10, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —B(ORd)2, —C1-6alkyl, or C1-6haloalkyl.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The compound of any one of claims 1-50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R10 is independently —F, —OH, —OMe, —B(OH)2, methyl, or —CF3.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 1-51, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R6 is hydrogen, methyl, ethyl, propyl, or —CH2CH2OH.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The compound of any one of claims 1-52, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R7 is

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The compound of any one of claims 1-47, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R6 and R7 are taken together with the nitrogen atom to which they are attached to form a C2-15heterocycloalkyl optionally substituted with one, two, or three R11.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 54)

The compound of any one of claims 1-47 or 54, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R6 and R7 are taken together with the nitrogen atom to which they are attached to form aziridine, azetidine, pyrrolidine, piperidine, azepane, morpholine, oxazepane, 8-azabicyclo[3.2.1]octane, or 3-azabicyclo[5.1.0]octane; which is optionally substituted with one, two, or three R11.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 54, 55)

The compound of any one of claims 1-47 or 54-55, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R6 and R are taken together with the nitrogen atom to which they are attached to form pyrrolidine, piperidine, azepane, or morpholine; which is optionally substituted with one, two, or three R11.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 54, 55, 56)

The compound of any one of claims 1-47 or 54-56, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R6 and R are taken together with the nitrogen atom to which they are attached to form pyrrolidine or piperidine; which is optionally substituted with one, two, or three R11.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 54, 55, 56, 57)

The compound of any one of claims 1-47 or 54-57, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R6 and R7 are taken together with the nitrogen atom to which they are attached to form piperidine; which is optionally substituted with one, two, or three R11.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The compound of any one of claims 1-47, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R11′ is independently oxo, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —NRS(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —OC(═O)ORb, —C(═O)NRbRc, —CH2C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, —OP(═O)(OR)(OR), —B(ORd)2, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, C1-6cyanoalkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C2-7heterocycloalkyl, aryl, heteroaryl, C1-6alkyl(aryl), C1-6alkyl(heteroaryl), C1-6alkyl(C3-8cycloalkyl), or C1-6alkyl(C2-7heterocycloalkyl);
p is 0 or 1;
q is 0 to 4; and
s is 0 to 3.

### Claim 60 (depends on 59)

The compound of claim 59, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein p is 0 and q is 2.

### Claim 61 (depends on 59)

The compound of claim 59, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein p is 0 and q is 3.

### Claim 62 (depends on 59)

The compound of claim 59, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein p is 1 and q is 1.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The compound of any one of claims 1-47 or 54-62, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R11 and R11′ is independently oxo, halogen, —CN, —OH, —ORa, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRbRc, —CH2C(═O)NRbRc, —OC(═O)NRbRc, —NRbC(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, —OP(═O)(ORb)(ORb), —B(ORd)2, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, C1-6cyanoalkyl, or C3-8cycloalkyl.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The compound of any one of claims 1-47 or 54-63, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R11 and R11′ is independently oxo, halogen, —CN, —OH, —ORa, —NRbRc, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRbRc, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —C(═O)NRbRc, —CH2C(═O)NRbRc, —NRbC(═O)Ra, —NRbC(═O)ORb, —OP(═O)(OR)(OR), —B(ORd)2, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6heteroalkyl, C1-6cyanoalkyl, or C3-8cycloalkyl.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The compound of any one of claims 1-47 or 54-64, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R11 and R11′ is independently oxo, —F, —Cl, —CN, —OH, —OMe, —NH2, —NMe2, —C(═O)Me, —OC(═O)Me, —C(═O)OH, —C(═O)OMe, —C(═O)OEt, —C(═O)OtBu, —C(═O)NH2, —CH2C(═O)NH2, —NHS(═O)2Me, —NHS(═O)2NH2, —S(═O)2NH2, —S(═O)2NHMe, —S(═O)2Me, —NHC(═O)Me, —OP(═O)(OH)(OH), —B(OH)2, methyl, ethyl, iso-propyl, —CF3, —CHF2, —CH2F, —CH2OH, —CH2CH2OH, —CH2CH2CH2OH, —CH2OCH3, —CH2CH2OCH3, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound of any one of claims 1-47 or 54-65, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R11 and R11′ is independently —F, —OH, —NH2, —OC(═O)Me, —C(═O)OH, —OP(═O)(OH)(OH), methyl, ethyl, —CH2OH, —CH2CH2OH, —CH2OCH3, or cyclopropyl.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The compound of any one of claims 1-47 or 54-66, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R11 and R11′ is independently —F, —OH, —NH2, —C(═O)OH, methyl, or —CH2OH.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The compound of any one of claims 1-47 or 54-67, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R11 and R11′ is independently —OH or —CH2OH.

### Claim 69 (depends on 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The compound of any one of claims 59-68, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein s is 1 to 2.

### Claim 70 (depends on 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The compound of any one of claims 59-69, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein s is 1.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The compound of any one of claims 1-47, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 71)

The compound of any one of claims 1-47 or 71, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof,

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 71, 72)

The compound of any one of claims 1-47 or 71-72, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 71, 72, 73)

The compound of any one of claims 1-47 or 71-73, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein

### Claim 75

A compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from the group consisting of:

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

A pharmaceutical composition comprising a compound of any one of claims 1-75, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

A method of treating an infection in a subject, comprising administering to the subject a compound of any one of claims 1-75, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

### Claim 78 (depends on 76)

A method of treating an infection in a subject, comprising administering to the subject a pharmaceutical composition of claim 76.

### Claim 79 (depends on 77, 78)

The method of claim 77 or 78, wherein the infection is a viral infection.

### Claim 80 (depends on 77, 78, 79)

The method of any one of claims 77-79, wherein the infection is caused by the hepatitis B virus.

### Claim 81 (depends on 77, 78, 79, 80)

The method of any one of claims 77-80, wherein the infection is hepatitis B.
